These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21068431)

  • 1. Sex hormones and colorectal cancer: what have we learned so far?
    Lin JH; Giovannucci E
    J Natl Cancer Inst; 2010 Dec; 102(23):1746-7. PubMed ID: 21068431
    [No Abstract]   [Full Text] [Related]  

  • 2. [Osteoporosis in castration therapy--a neglected field].
    Bratt O; Akesson K
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
    Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
    J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Deprivation Therapy-Linked Cardiovascular Disease Risk: Still Unresolved.
    Azvolinsky A
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26341000
    [No Abstract]   [Full Text] [Related]  

  • 5. Androgen-deprivation therapy and cardiovascular harm: let's not throw out the baby with the bathwater.
    Nguyen PL
    Eur Urol; 2014 Apr; 65(4):710-2. PubMed ID: 23498063
    [No Abstract]   [Full Text] [Related]  

  • 6. Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration.
    Seiger R; Hahn A; Hummer A; Kranz GS; Ganger S; Woletz M; Kraus C; Sladky R; Kautzky A; Kasper S; Windischberger C; Lanzenberger R
    Psychoneuroendocrinology; 2016 Dec; 74():371-379. PubMed ID: 27744092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostatic cancer and its androgen-dependency].
    Shimazaki J; Isaka S; Akimoto S; Sumiya H; Ichikawa T; Akakura K; Furuya Y
    Gan No Rinsho; 1989 May; Spec No():268-76. PubMed ID: 2513430
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
    Schooling CM; Sembajwe G; Agalliu I
    Eur Urol; 2013 Sep; 64(3):e59-60. PubMed ID: 23623050
    [No Abstract]   [Full Text] [Related]  

  • 9. Is hormone ablation still the right choice for advanced prostate cancer?
    Fitzpatrick JM
    BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
    [No Abstract]   [Full Text] [Related]  

  • 10. Choice of first-line treatment for metastatic prostate cancer.
    Prescrire Int; 2013 Feb; 22(135):51. PubMed ID: 23444511
    [No Abstract]   [Full Text] [Related]  

  • 11. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 12. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exogenous and endogenous hormones and breast cancer.
    Chen WY
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):573-85. PubMed ID: 18971119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to C. Mary Schooling, Grace Sembajwe and Ilir Agalliu's letter to the editor Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
    Jespersen CG; Nørgaard M; Borre M
    Eur Urol; 2013 Sep; 64(3):e61. PubMed ID: 23622775
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemoprevention of breast cancer.
    O'Regan RM
    Cancer Treat Res; 2000; 103():183-207. PubMed ID: 10948447
    [No Abstract]   [Full Text] [Related]  

  • 17. Hormonal control of gastric and colorectal cancer in man.
    Morris DL; Watson SA; Durrant LG; Harrison JD
    Gut; 1989 Apr; 30(4):425-9. PubMed ID: 2653970
    [No Abstract]   [Full Text] [Related]  

  • 18. [Total androgen blockade--concept, theory, method and clinical application].
    Ozono S; Hirao Y
    Nihon Rinsho; 1998 Aug; 56(8):2129-34. PubMed ID: 9750521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical review 37: Endocrine treatment of prostate cancer.
    Santen RJ
    J Clin Endocrinol Metab; 1992 Sep; 75(3):685-9. PubMed ID: 1517354
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.